Skip to main content
. 2013 Jun 12;33(24):10182–10190. doi: 10.1523/JNEUROSCI.0284-13.2013

Table 3.

Sleep data for baseline and test nights in Val/Val and Met carriers (mean ± SD)

(min) Baseline night
Test night
Statistics for allelic group difference
Val/Val (n = 14) Met carriers (n = 15) Val/Val (n = 14) Met carriers (n = 15)
Stage 2 duration 179.1 ± 27.9 188.4 ± 34.7 187.7 ± 25.4 179.8 ± 36.8 F(1,21) = 0.00, p = 0.96
Stage 3 duration 169.3 ± 34 164.7 ± 45.4 161 ± 15.4 167.8 ± 41 F(1,21) = 0.15, p = 0.71
REM duration 98.3 ± 21.3 103.3 ± 22.6 102.2 ± 28.9 119.7 ± 14.7 F(1,21) = 2.53, p = 0.13
Stage 2 latency 8.9 ± 6.3 12.4 ± 11.5 12.4 ± 11.2 12.3 ± 10.4 F(1,27) = 0.32, p = 0.58
Stage 3 latency 15.3 ± 7.3 19.5 ± 13.6 15.9 ± 11.5 17.4 ± 10.6 F(1,27) = 0.73, p = 0.40
REM latency 117.8 ± 54.9 95 ± 13.6 85.1 ± 24.8 88.8 ± 38.3 F(1,27) = 0.60, p = 0.43
Total time in bed 494.5 ± 13.6 497.1 ± 12.7 503.3 ± 5.7 505.3 ± 10.1 F(1,27) = 0.18, p = 0.68
Sleep duration 446.7 ± 31 456.4 ± 22.7 451 ± 38.2 467.3 ± 23.1 F(1,21) = 3.11, p = 0.09
First NREM period
    Stage 2 duration 15 ± 15 15.4 ± 11.3 9.6 ± 5.0 9.7 ± 4.6 F(1,27) = 0.00, p = 0.95
    Stage 3 duration 57.5 ± 15.1 51.5 ± 16.4 56.7 ± 15.0 48.2 ± 10.4 F(1,27) = 3.73, p = 0.06
    Total period duration 81.9 ± 33.6 69.4 ± 17.5 67.2 ± 17.3 58.4 ± 10.9 F(1,27) = 2.61, p = 0.12
Q1
    Stage 2 duration 6.6 ± 3.9 6.2 ± 2.7 5 ± 1.7 5.7 ± 1.7 F(1,27) = 0.08, p = 0.78
    Stage 3 duration 11.7 ± 6.3 10.9 ± 5.2 11.9 ± 4.1 9.2 ± 5.1 F(1,27) = 1.45, p = 0.24
    Total period duration 21.9 ± 8.7 17.5 ± 4.3 16.9 ± 4.3 15.2 ± 4.5 F(1,27) = 3.13, p = 0.09
HHS Vulnerability Disclosure